Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Satolli

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy|May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
Dermatology and Therapy|July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology|June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched StudyFrancesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy|May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
Dermatology and Therapy|July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology|June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched StudyFrancesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
Pageof 9